The World Health Organisation (WHO) approval for the emergency use authorisation (EUA) to Bharat Biotech-manufactured Covid-19 vaccine- Covaxin is likely to be delayed till October 5, according to reports.

The Strategic Advisory Group of Experts on Immunization (SAGE) will be meeting on October 5 to granting emergency approval to Covaxin. Hanna Nohynek, SAGE member will be introducing session objective setting, an update on regulatory decisions and an overview of Working Group deliverables.

Covaxin is one of the six vaccines that have received emergency use authorisation from India’s drug regulator and is being used in the nationwide inoculation programme, along with Covishield and Sputnik V. The Centre had told Rajya Sabha in July that all documents required for the WHO’s Emergency Use Listing  have been submitted by Bharat Biotech as of July 9, and the global health body had commenced the review process. Meanwhile, Bharat Biotech on Friday said it has submitted all the data to WHO for Emergency Use Listing) of its COVID-19 vaccine Covaxin and is awaiting feedback from the UN Public Health Agency. 

In a series of tweets, Bharat Biotech said that Covaxin clinical trial was fully compiled and available in June 2021. The Bharat Biotech tweet reads as under:"COVAXIN clinical trial data was fully compiled and available in June 2021. All Data was submitted for Emergency Use Listing (EUL) Application to World Health Organization in early July. We have responded to any clarifications sought by WHO and are awaiting further feedback.”

Karnataka COVID-19 vaccination surpasses 26.92 lakh doses in single day

Seeing Record Vaccination on his birthday, PM Modi said- 'Every Indian will be proud'

Many essential medicines GST free, know what happened to petrol-diesel?